Sugi Predict

Sugi Predict / Compounds / SCHEMBL746205

SCHEMBL746205

SCHEMBL746205

C[C@H]1C[C@@H](O)CN1C(=O)O

nearest known ligand 0.48

Predicted protein targets (top 12)

geneUniProtsupporting neighboursconfidence
▸ ATM Q13315 1/20 0.48
▸ PIK3CD O00329 5/20 0.41
▸ DPP4 P27487 7/20 0.37
▸ DPP8 Q6V1X1 7/20 0.37
▸ DPP9 Q86TI2 7/20 0.37
▸ MAPT P10636 1/20 0.35
▸ TSHR P16473 1/20 0.35
▸ DPP7 Q9UHL4 1/20 0.35
▸ FAP Q12884 1/20 0.35
▸ RIPK1 Q13546 1/20 0.35
▸ GAA P10253 1/20 0.33
▸ ALDH1A1 P00352 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1923005 1.00 ATM (0.48) ATMPIK3CDDPP4DPP8DPP9
SCHEMBL744198 1.00 ATM (0.48) ATMPIK3CDDPP4DPP8DPP9
SCHEMBL17760540 1.00 ATM (0.48) ATMPIK3CDDPP4DPP8DPP9
SCHEMBL4531927 1.00 ATM (0.48) ATMPIK3CDDPP4DPP8DPP9
SCHEMBL3673559 1.00 ATM (0.48) ATMPIK3CDDPP4DPP8DPP9
SCHEMBL25286686 1.00 ATM (0.48) ATMPIK3CDDPP4DPP8DPP9
SCHEMBL5795993 1.00 ATM (0.48) ATMPIK3CDDPP4DPP8DPP9
SCHEMBL418951 0.82 ATM (0.59) ATMPIK3CDDPP4DPP8DPP9
SCHEMBL16751022 0.82 ATM (0.59) ATMPIK3CDDPP4DPP8DPP9
SCHEMBL17511112 0.80 ATM (0.42) ATMPIK3CDDPP4DPP8DPP9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240150362-A1 Substituted Pyrrolotriazines MOLECURE S.A. (PL) 2024-05-09 — — US disclosed
WO-2024042494-A1 SUBSTITUTED PYRROLOTRIAZINES MOLECURE SA (PL) 2024-02-29 — — WO disclosed
WO-2024039858-A1 ESTROGEN RECEPTOR MODULATORS AND USES THEREOF OLEMA PHARMACEUTICALS, INC. (US) 2024-02-22 — — WO disclosed
WO-2024030633-A1 COMPOSITIONS AND METHODS FOR INHIBITION OF KRAS THERAS, INC. (US) 2024-02-08 — — WO disclosed
US-20230203060-A1 FUSED TRICYCLIC COMPOUND, PHARMACEUTICAL COMPOSITION THEREOF, AND USE THEREOF GENFLEET THERAPEUTICS (SHANGHAI) INC. (CN) 2023-06-29 — — US disclosed
WO-2023076849-A1 INHIBITORS OF EPIDERMAL GROWTH FACTOR RECEPTOR ORIC PHARMACEUTICALS, INC. (US) 2023-05-04 — — WO disclosed
WO-2023070064-A1 O-GLCNACASE (OGA) INHIBITOR COMBINATION THERAPY ELI LILLY AND COMPANY (US) 2023-04-27 — — WO disclosed
EP-4159739-A1 FUSED TRICYCLIC COMPOUND, PHARMACEUTICAL COMPOSITION THEREOF, AND USE THEREOF Genfleet Therapeutics (Shanghai) Inc. (CN) 2023-04-05 — — EP disclosed
EP-3921316-A1 BICYCLIC ETHER O-GLYCOPROTEIN-2-ACETAMIDO-2-DEOXY-3-D-GLUCOPYRANOSIDASE INHIBITORS Biogen MA Inc. (US) 2021-12-15 — — EP disclosed
EP-3856739-A1 6-FLUORO-2-METHYLBENZO[D]THIAZOL-5-YL COMPOUNDS Eli Lilly and Company (US) 2021-08-04 — — EP disclosed
EP-1565436-B1 3-AMINOPYRROLIDINE DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTORS INCYTE CORP (US) 2012-04-25 — — EP disclosed
EP-2431357-A2 3-Aminopyrrolidine Derivatives as Modulators of Chemokine Receptors Incyte Corporation (US) 2012-03-21 — — EP disclosed
US-20110251168-A1 3-AMINOPYRROLIDINE DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTORS INCYTE CORPORATION 2011-10-13 — — US disclosed
US-7985730-B2 3-aminopyrrolidine derivatives as modulators of chemokine receptors INCYTE CORPORATION (US) 2011-07-26 — — US disclosed
US-7834021-B2 3-aminopyrrolidine derivatives as modulators of chemokine receptors INCYTE CORPORATION (US) 2010-11-16 — — US disclosed
US-7649001-B2 Fused benzene derivative and use TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-01-19 — — US disclosed
US-20090247474-A1 3-Aminopyrrolidine Derivatives As Modulators Of Chemokine Receptors INCYTE CORPORATION 2009-10-01 — — US disclosed
US-20060252751-A1 3-Aminopyrrolidine derivaties as modulators of chemokine receptors INCYTE HOLDINGS CORPORATION 2006-11-09 — — US disclosed
US-20060106067-A1 Fused benzene derivative and use TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2006-05-18 — — US disclosed
EP-1553074-A1 FUSED BENZENE DERIVATIVE AND USE Takeda Pharmaceutical Company Limited (JP) 2005-07-13 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060252751-A1 3-Aminopyrrolidine derivaties as modulators of chemokine receptors CCR2, CXCR3, CCR5 ATM 2071/4885PIK3CD 3629/4885DPP4 2633/4885
US-20060106067-A1 Fused benzene derivative and use AR, NR5A1, CBR3 ATM 1839/4885PIK3CD 4051/4885DPP4 4424/4885
US-20240150362-A1 Substituted Pyrrolotriazines USP7, UBA7, USP5 ATM 3496/4885PIK3CD 2829/4885DPP4 750/4885
US-20230203060-A1 FUSED TRICYCLIC COMPOUND, PHARMACEUTICAL COMPOSITION THEREOF, AND USE THEREOF KRAS, NRAS, TP53 ATM 1709/4885PIK3CD 46/4885DPP4 2706/4885
US-20090247474-A1 3-Aminopyrrolidine Derivatives As Modulators Of Chemokine Receptors CCR2, CXCR3, CCR5 ATM 2379/4885PIK3CD 3597/4885DPP4 2716/4885
US-20110251168-A1 3-AMINOPYRROLIDINE DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTORS CCR2, CXCR3, CCR5 ATM 2379/4885PIK3CD 3597/4885DPP4 2716/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.